BC Week In Review | Feb 23, 2018
Clinical News

Positive CHMP vote likely for Clovis' PARP inhibitor

Clovis Oncology Inc. (NASDAQ:CLVS) said EMA's CHMP communicated a "positive trend vote" for an MAA for rucaparib (CO-338) to treat platinum-sensitive, BRCA-mutant advanced ovarian cancer. Clovis expects a formal vote on the MAA at CHMP's...
Items per page:
1 - 1 of 1